Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Dynavax Technologies Co. (NASDAQ:DVAX – Free Report) by 1.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 385,730 shares of the biopharmaceutical company’s stock after purchasing an additional 3,863 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank owned 0.30% of Dynavax Technologies worth $3,784,000 at the end of the most recent quarter.
Other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Dynavax Technologies by 1.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,312 shares of the biopharmaceutical company’s stock valued at $631,000 after buying an additional 1,077 shares during the last quarter. Arizona State Retirement System raised its stake in shares of Dynavax Technologies by 3.6% during the first quarter. Arizona State Retirement System now owns 35,119 shares of the biopharmaceutical company’s stock valued at $345,000 after acquiring an additional 1,216 shares during the last quarter. Commonwealth Equity Services LLC boosted its holdings in shares of Dynavax Technologies by 2.7% during the fourth quarter. Commonwealth Equity Services LLC now owns 54,158 shares of the biopharmaceutical company’s stock worth $576,000 after purchasing an additional 1,448 shares during the period. Advisors Asset Management Inc. grew its stake in shares of Dynavax Technologies by 498.0% in the first quarter. Advisors Asset Management Inc. now owns 2,362 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 1,967 shares during the last quarter. Finally, California State Teachers Retirement System increased its holdings in Dynavax Technologies by 1.3% during the 3rd quarter. California State Teachers Retirement System now owns 149,988 shares of the biopharmaceutical company’s stock valued at $1,566,000 after purchasing an additional 1,989 shares during the period. Hedge funds and other institutional investors own 99.45% of the company’s stock.
Insider Activity at Dynavax Technologies
In other news, Director Andrew A. F. Hack sold 500,000 shares of the firm’s stock in a transaction on Wednesday, June 14th. The stock was sold at an average price of $12.68, for a total transaction of $6,340,000.00. Following the completion of the transaction, the director now directly owns 2,415,000 shares in the company, valued at $30,622,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Dynavax Technologies news, Director Andrew A. F. Hack sold 500,000 shares of the firm’s stock in a transaction dated Wednesday, June 14th. The shares were sold at an average price of $12.68, for a total transaction of $6,340,000.00. Following the completion of the sale, the director now directly owns 2,415,000 shares in the company, valued at approximately $30,622,200. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Andrew A. F. Hack sold 1,500,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 8th. The stock was sold at an average price of $14.39, for a total transaction of $21,585,000.00. Following the completion of the transaction, the director now owns 915,000 shares in the company, valued at approximately $13,166,850. The disclosure for this sale can be found here. Insiders sold a total of 2,050,661 shares of company stock valued at $28,676,137 in the last 90 days. Corporate insiders own 2.62% of the company’s stock.
Dynavax Technologies Stock Down 0.3 %
Analysts Set New Price Targets
A number of brokerages have recently weighed in on DVAX. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Dynavax Technologies in a research report on Friday, August 4th. StockNews.com began coverage on shares of Dynavax Technologies in a report on Thursday, May 18th. They issued a “hold” rating on the stock. Finally, JMP Securities upped their price objective on shares of Dynavax Technologies from $24.00 to $25.00 and gave the stock an “outperform” rating in a report on Friday, August 4th. One equities research analyst has rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, Dynavax Technologies currently has an average rating of “Moderate Buy” and an average target price of $24.33.
Get Our Latest Stock Report on DVAX
Dynavax Technologies Profile
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.
Featured Articles
- Five stocks we like better than Dynavax Technologies
- Trading Halts Explained
- MarketBeat Week in Review – 8/7 – 8/11
- How to Calculate Inflation Rate
- 3 Retailers To Watch Closely Next Week
- How to Invest in Fertilizer
- Investing in Coffee: 3 Great Strategies to Consider
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
